X |
Filing Date |
Trade Date |
Ticker |
Company Name | Industry | Ins |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 M | 2026-01-13 | GAM | General American Investors Co Inc | Closed-End Funds | 3 | P - Purchase | $24.99 | +81,325 | 1,992,873 | +4% | +$2,031,930 | |||||
| 5 M | 2025-11-14 | ACVA | Acv Auctions Inc. | Business Services | 4 | P - Purchase | $5.78 | +1,058,437 | 5,947,475 | +22% | +$6,118,506 | |||||
| 2 | 2025-12-17 | SPT | Sprout Social, Inc. | Prepackaged Software | 2 | P - Purchase | $10.90 | +184,645 | 1,110,000 | +20% | +$2,012,585 | |||||
| 42 M | 2026-01-09 | TPVG | Triplepoint Venture Growth Bdc Corp. | Closed-End Funds | 2 | P - Purchase | $6.37 | +2,864,508 | 4,543,608 | +171% | +$18,238,062 | |||||
| 3 | 2026-01-09 | ADC | Agree Realty Corp | Real Estate Investment Trusts | 3 | P - Purchase | $71.23 | +39,500 | 1,241,225 | +3% | +$2,813,680 | |||||
| 2 | 2026-01-05 | LB | Landbridge Co LLC | Oil Royalty Traders | 2 | P - Purchase | $46.66 | +2,993 | 290,420 | +1% | +$139,656 | |||||
| 3 | 2026-01-05 | WBI | Waterbridge Infrastructure LLC | Oil & Gas Field Services | 3 | P - Purchase | $20.13 | +11,865 | 314,365 | +4% | +$238,844 | |||||
| 5 M | 2025-12-31 | HYPD | Hyperion Defi, Inc. | Pharmaceutical Preparations | 4 | P - Purchase | $3.23 | +189,204 | 698,493 | +37% | +$611,458 | |||||
| 2 M | 2025-11-06 | LTC | Ltc Properties Inc | Real Estate Investment Trusts | 2 | P - Purchase | $34.80 | +15,000 | 55,460 | +37% | +$521,960 | |||||
| 3 M | 2025-12-31 | LSAK | Lesaka Technologies Inc | Functions Related to Depository Banking | 2 | P - Purchase | $4.99 | +1,830,500 | 2,575,615 | +246% | +$9,130,204 |
X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-01-13 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $29.83 | +1,800 | 5,604,102 | 0% | +$53,694 | ||||||
| M | 2026-01-12 | WRB | Berkley W R Corp | Mitsui Sumitomo Insurance Co Ltd | 10% | P - Purchase | $68.58 | +811,041 | 52,726,504 | +2% | +$55,622,807 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Foley Todd | Dir, 10% | P - Purchase | $18.00 | +232,870 | 4,235,403 | +6% | +$4,191,660 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.P. | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Gadicke Ansbert | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
| M | 2026-01-12 | SPRU | Spruce Power Holding Corp | Steel Partners Holdings L.P. | 10% | P - Purchase | $5.07 | +19,920 | 3,217,389 | +1% | +$100,940 | |||||
2026-01-13 | PRIVX | Private Shares Fund | Radcliffe Mark | Dir | P - Purchase | $47.11 | +1,061 | 1,061 | New | +$50,000 | ||||||
2026-01-06 | IVFH | Innovative Food Holdings Inc | Schubert Gary | CEO | P - Purchase | $0.30 | +166,666 | 532,569 | +46% | +$50,000 | ||||||
2026-01-12 | TCI | Transcontinental Realty Investors Inc | American Realty Investors Inc | 10% | P - Purchase | $55.50 | +70,023 | 6,791,741 | +1% | +$3,886,277 | ||||||
2026-01-12 | GRX | Gabelli Healthcare & Wellnessrx Trust | Gabelli Mario J | Control Person of Adviser | P - Purchase | $9.58 | +4,810 | 574,831 | +1% | +$46,080 |
X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-01-06 | IVFH | Innovative Food Holdings Inc | Schubert Gary | CEO | P - Purchase | $0.30 | +166,666 | 532,569 | +46% | +$50,000 | ||||||
2026-01-13 | ASST | Strive, Inc. | Cole Matthew Ryan | CEO | P - Purchase | $0.92 | +500,000 | 1,200,380 | +71% | +$459,350 | ||||||
2026-01-12 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $4.35 | +20,000 | 1,161,064 | +2% | +$86,904 | ||||||
| M | 2026-01-11 | YYAI | Airwa Inc. | Zhou Hongyu | Dir | P - Purchase | $1.35 | +1,109,922 | 1,601,489 | +226% | +$1,499,213 | |||||
2026-01-12 | COSM | Cosmos Health Inc. | Siokas Grigorios | CEO, 10% | P - Purchase | $0.50 | +113,185 | 7,244,979 | +2% | +$57,000 | ||||||
| M | 2026-01-09 | MIGI | Mawson Infrastructure Group Inc. | Endeavor Blockchain, LLC | 10% | P - Purchase | $4.56 | +182,018 | 85,297 | -188% | +$829,562 | |||||
| M | 2025-12-26 | MIGI | Mawson Infrastructure Group Inc. | Endeavor Blockchain, LLC | 10% | P - Purchase | $4.48 | +205,000 | 63,279 | -145% | +$917,550 | |||||
2026-01-07 | GTE | Gran Tierra Energy Inc. | Lm Asset (Im) Inc. | 10% | P - Purchase | $3.87 | +80,000 | 4,381,750 | +2% | +$309,712 | ||||||
| M | 2026-01-07 | YYAI | Airwa Inc. | Zhou Hongyu | Dir | P - Purchase | $1.16 | +189,097 | 491,567 | +63% | +$219,807 | |||||
2026-01-07 | SQNS | Sequans Communications | Asher Daniel | 10% | P - Purchase | $4.91 | +21,900 | 1,706,847 | +1% | +$107,514 |
X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-01-12 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | S - Sale+OE | $28.25 | -110,000 | 700,438 | -14% | -$3,107,229 | |||||
2026-01-12 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $6.07 | -80,554 | 1,373,182 | -6% | -$489,019 | ||||||
| D | 2026-01-12 | CRWV | Coreweave, Inc. | McBee Brannin | Chief Development Officer | S - Sale+OE | $88.77 | -8,835 | 58,300 | -13% | -$784,274 | |||||
| D | 2026-01-12 | CRWV | Coreweave, Inc. | McBee Brannin | Chief Development Officer | S - Sale+OE | $88.77 | -26,000 | 0 | -100% | -$2,308,081 | |||||
| D | 2026-01-12 | CRWV | Coreweave, Inc. | McBee Brannin | Chief Development Officer | S - Sale+OE | $88.77 | -26,000 | 0 | -100% | -$2,308,082 | |||||
| D | 2026-01-12 | CRWV | Coreweave, Inc. | McBee Brannin | Chief Development Officer | S - Sale+OE | $88.77 | -105,835 | 248,664 | -30% | -$9,395,437 | |||||
| D | 2026-01-12 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $21.92 | -200,000 | 1,654,597 | -11% | -$4,384,000 | |||||
| D | 2026-01-14 | MTUS | Metallus Inc. | Westbrooks Kristopher R | Pres, COO | S - Sale+OE | $20.06 | -10,932 | 189,076 | -5% | -$219,296 | |||||
2026-01-09 | JCAP | Jefferson Capital, Inc. / De | Burton David M. | SEE REMARKS | S - Sale | $20.50 | -385,000 | 3,392,500 | -10% | -$7,892,500 | ||||||
| D | 2026-01-12 | TXRH | Texas Roadhouse, Inc. | Morgan Gerald L. | CEO, Exec VICE COB | S - Sale+OE | $187.13 | -5,000 | 96,774 | -5% | -$935,650 |
X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-01-13 | IMRX | Immuneering Corp | Neufeld Leah R | CHIEF PEOPLE OFFICER | P - Purchase | $4.15 | +2,626 | 25,970 | +11% | +$10,906 | ||||||
2026-01-13 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $29.83 | +1,800 | 5,604,102 | 0% | +$53,694 | ||||||
| D | 2025-12-18 | GBCS | Selectis Health, Inc. | Baller Lance | Dir, 10% | P - Purchase | $2.20 | +6,192 | 294,374 | +2% | +$13,622 | |||||
| M | 2026-01-12 | WRB | Berkley W R Corp | Mitsui Sumitomo Insurance Co Ltd | 10% | P - Purchase | $68.58 | +811,041 | 52,726,504 | +2% | +$55,622,807 | |||||
| DM | 2026-01-12 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | S - Sale+OE | $28.25 | -110,000 | 700,438 | -14% | -$3,107,229 | |||||
| DM | 2026-01-13 | OLMA | Olema Pharmaceuticals, Inc. | Myles David C. | CH. DISCOV., NON-CLIN DEV OFF | M - OptEx | $4.87 | +100,000 | 700,438 | +17% | +$487,000 | |||||
| D | 2026-01-12 | CRMD | Cormedix Inc. | Lefkowitz Steven W | Dir | M - OptEx | $5.63 | +15,000 | 127,650 | +13% | +$84,450 | |||||
2026-01-12 | HP | Helmerich & Payne, Inc. | Lindsay John W | CEO | F - Tax | $30.58 | -3,410 | 753,122 | 0% | -$104,278 | ||||||
2026-01-12 | HP | Helmerich & Payne, Inc. | Bell John R. | EVP, EASTERN HEMISPHERE LAND | F - Tax | $30.58 | -874 | 256,982 | 0% | -$26,727 | ||||||
2026-01-12 | ATRA | Atara Biotherapeutics, Inc. | Panacea Innovation Ltd | 10% | S - Sale | $6.07 | -80,554 | 1,373,182 | -6% | -$489,019 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |